risks with glp 1 GLP-1 Agonists In Obesity GLP-1 Muscle Loss Explained |

Mitchell JL, Mollan SP, Vijay V, Sinclair AJ

It was given to 29 women who were overweight or obese in a dose of 5mg or 15mg/day and compared to placebo

Market Segmentation Drug Type Insights (Revenue, USD BN, 2021 - 2033) Exenatide Liraglutide Sitagliptin Saxagliptin Alogliptin Others Disease Indication Insights (Revenue, USD BN, 2021 - 2033) Type 2 Diabetes Mellitus (T2DM) Weight Management Others Distribution Channel Insights (Revenue, USD BN, 2021 - 2033) Online Pharmacies Retail Pharmacies Hospital Pharmacies Regional Insights (Revenue, USD BN, 2021 - 2033) North America U.S

This was no longer a glucose drug

doi: 10.1016/j.cmet.2017.04.013

If the glycemic goals are not achieved, the dose can be increased to 1.8 mg per day83)